Merit Medical Systems (MMSI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Petusky from Barrington maintained a Buy rating on the stock and has a $111.00 price target.
Michael Petusky has given his Buy rating due to a combination of factors including Merit Medical Systems’ anticipated revenue growth and profitability. The company is expected to report an 8.4% increase in revenue for the first quarter of 2025 compared to the same period last year, with significant contributions from their cardiac intervention and endoscopy devices segments. Additionally, Merit Medical is projected to generate $29 million in free cash flow, an improvement from the previous year’s $24.5 million.
Despite the potential risks associated with tariffs, particularly concerning the revenue generated in China, Petusky remains optimistic about the company’s long-term growth initiatives. These initiatives aim for 5-7% annual organic revenue growth and a notable improvement in operating margins. The recent launch of the Wrapsody device, which could significantly impact the market for dialysis patients, also contributes to the positive outlook. Consequently, Petusky maintains a 12-month price target of $111 for MMSI shares, reflecting confidence in the company’s strategic direction and financial health.
In another report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $111.00 price target.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MMSI in relation to earlier this year.